Just a couple of more points of interest . I spent a bit of time...

Just a couple of more points of interest . I spent a bit of time yesterday reading the annual report . Maybe nothing new in there , but its easy to forget things and I guess this is a good summation of things .

1. Estimated market in the developed world for Onychomycosis ( rotten toenails ) is quoted at 3.7 bill - in 2018 ( that's much more than I thought....and is a useful parameter in trying to value the IP of their anti fungal compound . )

2. Cash on hand & short term receivables 7.4 mill ( which would include the R& D rebate of some per June 2021 of close to 4 mill

3. They are also discussing selling off the company owned glasshouse - which they value at some 2.8 mill ( these have been returning income of some $690 k p/a - and have returned 1 mill + last year )

So they aren't exactly starved for cash at the moment ....... however time does go quickly

Heres a couple of extracts from the Annual report ...which makes good reading I think
( assuming the contents are read in good faith )